Skip to main content
DrugPrice

Tecfidera

Dimethyl Fumarate

Generic availableMultiple Sclerosisby Biogen
$4,103.00
avg cost per claim
-28.4% year-over-year
$1.8B
Medicare Spending
428,000
Total Claims
38,000
Beneficiaries
$46,211.00
Annual Cost/Patient

Why Tecfidera Costs $4,103.00 Per Claim

Tecfidera (Dimethyl Fumarate) is used to treat multiple sclerosis. According to CMS Medicare Part D spending data, the program spent $1.8B on this drug, covering 38,000 beneficiaries across 428,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Dimethyl Fumarate or talk to their doctor about therapeutic alternatives that may cost less.

Spending on Tecfidera decreased by 28.4% year-over-year, likely due to generic competition reducing prices.

Price Breakdown

Avg cost per claim (30-day)$4,103.00
Avg annual cost per patient$46,211.00
Total Medicare spending$1.8B
Total claims428,000
Beneficiaries38,000

Drug Details

Brand Name
Tecfidera
Generic Name
Dimethyl Fumarate
Active Ingredient
DIMETHYL FUMARATE
Manufacturer
Biogen
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Condition
Multiple Sclerosis
FDA Application
NDA204063

Frequently Asked Questions

Tecfidera (Dimethyl Fumarate) costs an average of $4,103.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $46,211.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Yes, a generic version of Tecfidera (Dimethyl Fumarate) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Dimethyl Fumarate.

Medicare Part D spent $1.8B on Tecfidera, covering 38,000 beneficiaries across 428,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Dimethyl Fumarate, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.